Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000260467 is a long non-coding RNA gene, annotated as "novel transcript, antisense to CCDC135 and GPR97." This lncRNA is transcribed in the antisense orientation relative to the coding genes CCDC135 and GPR97[8][3][5]. It is catalogued in multiple genomic databases, including Ensembl, GeneCards, and Open Targets Platform. There is currently no evidence that this RNA acts as a classical therapeutic target (such as a receptor, enzyme, transporter, or transcription factor), nor is there evidence of direct drug interactions, established roles in disease, or use as a clinical biomarker[8][3][5]. Its biological function and disease associations are uncharacterized, as is typical for many annotated lncRNAs. No notable safety concerns or therapeutic challenges are reported[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CCDC135 and GPR97 (ENSG00000260467).